NCT00445302View on ClinicalTrials.gov

Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions

Renal Impairment

Interventions

DRUG

plerixafor

Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection

Trial Locations (3)

55114

Prism Research, 1000 Westgate Dr. suite 149, Saint Paul

68131

Creighton University Medical Center, Omaha

92705

Apex Research of Riverside, Santa Ana

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00445302 - Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment | Biotech Hunter | Biotech Hunter